Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 16/20 | 0.51 |
| ▸ | STAT3 | P40763 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDE6D | O43924 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889790 | 0.89 | FFAR4 (0.41) | FFAR4STAT3MAPTPDE6D | |
| SCHEMBL4650113 | 0.86 | FFAR4 (0.62) | FFAR4 | |
| SCHEMBL6700661 | 0.83 | FFAR4 (0.42) | FFAR4STAT3PDE6D | |
| SCHEMBL13009721 | 0.82 | BCHE (0.38) | FFAR4STAT3MAPT | |
| SCHEMBL4936414 | 0.80 | FFAR4 (0.53) | FFAR4ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2989141 | 0.78 | ALDH1A1 (0.47) | FFAR4ALDH1A1MAPTPDE6D | |
| SCHEMBL13881960 | 0.78 | PDE6D (0.44) | ALDH1A1MAPTSMN1; SMN2PDE6D | |
| SCHEMBL4929882 | 0.77 | STAT3 (0.47) | STAT3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17028645 | 0.77 | FFAR4 (0.82) | FFAR4 | |
| SCHEMBL13009996 | 0.77 | BCHE (0.36) | FFAR4STAT3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | disclosed |
| US-6939990-B2 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | SDHA, GOT2, MDH2 | FFAR4 806/4885STAT3 3798/4885ALDH1A1 349/4885 |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | DDC, DAO, AADAT | FFAR4 816/4885STAT3 416/4885ALDH1A1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.